StemCells, Inc. (NASDAQ: STEM) is currently engaged in the clinical development of its innovative HuCNS-SC® platform technology as a potential treatment for both neurological and retinal disorders. The company’s top-line data from its phase I/II clinical trial in thoracic spinal cord injury showed measurable gains involving multiple sensory modalities and segments, including the conversion of two of the seven patients enrolled in the study from complete injuries to incomplete injuries following transplantation. For more information, visit the company’s website at www.stemcellsinc.com.